Medicine

Grants

Grants per year 1991 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2034

• 1284 Active
• 5978 Finished

Grants per year

Search results

• Active

  A Multicenter Randomized Controlled Trial of High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Stem Cell Transplant versus Best Available Approved Therapy for Treatment-Resistant Relapsing Multiple Sclerosis - Fixed Rate

  Georges, G. E. (PD/PI) & Cohen, B. A. (Co-Investigator)

  Benaroya Research Institute at Virginia Mason, National Institute of Allergy and Infectious Diseases

  2/1/24 → 1/31/28

  Project: Research project

• Elucidating the Role of cGAS-STING in Lung Tissue Repair and Remodeling

  Ridge, K. M. (PD/PI), Gottardi, C. J. (Co-Investigator), Winter, D. R. (Co-Investigator) & Ma, R. (Other)

  National Heart, Lung, and Blood Institute

  2/1/24 → 1/31/28

  Project: Research project

• Novel role of hepatic SEL1L-HRD1 ERAD in bile acid metabolism

  Fang, D. (PD/PI), Fang, D. (PD/PI), Green, R. (Co-Investigator) & Green, R. (Co-Investigator)

  University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases

  2/1/24 → 1/31/28

  Project: Research project

• High-Throughput Precision Identification of Cardiac Amyloidosis in a Diverse Population

  Ahmad, F. S. (PD/PI), Narang, A. (Co-Investigator) & Okwuosa, I. S. (Co-Investigator)

  Cedars-Sinai Medical Center, Gordon E. and Betty I. Moore Foundation

  2/1/24 → 1/31/26

  Project: Research project

• Prot #SBI-BSF-001: Collection of Plasma Samples Using Sodium Heparin from Subjects Undergoing Intravenous Busulfan Treatment

  Adekola, K. (PD/PI)

  Saladax Biomedical Inc

  1/31/24 → 1/31/27

  Project: Research project

• Prot #COVALENT-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia

  Abaza, Y. (PD/PI)

  PPD Investigator Services, LLC, Biomea Fusion Inc.

  1/30/24 → 1/30/27

  Project: Research project

• Prot #2022-06: ALT-FLOW II: A randomized, sham-controLled, clinical Trial For evaLuation Of the EdWards APTURE transcatheter shunt system

  Flaherty, J. D. (PD/PI)

  Edwards Lifesciences LLC

  1/30/24 → 1/30/27

  Project: Research project

• Prot #NU 23H06: A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients with Classical Hodgkin Lymphoma, Including Elderly Patients

  Winter, J. N. (PD/PI)

  Merck Sharp & Dohme LLC

  1/29/24 → 1/29/27

  Project: Research project

• Prot #VAC52416BAC3001: Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease

  Krueger, K. M. (PD/PI) & Nyaku, A. N. (PD/PI)

  Pharmaceutical Research Associates, Inc., Janssen Research & Development, LLC

  1/26/24 → 1/26/27

  Project: Research project

• Prot #KZR‑616‑202: A Phase 2b, Randomized, Controlled Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis

  Peleg, Y. A. (PD/PI) & Wadhwani, S. (PD/PI)

  PPD Investigator Services, LLC, Kezar Life Sciences, Inc.

  1/26/24 → 1/26/27

  Project: Research project

• Prot #D926XC00001: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-Negative Breast Cancer Who Have Residual Invasive Disease

  Stein, R. M. (PD/PI)

  AstraZeneca Pharmaceuticals LP

  1/25/24 → 1/25/27

  Project: Research project

• H3 histone oxidation is a new posttranslational modification linking heavy metal-induced metabolic changes and oncegenic epigenetic reprogramming

  Bonini, M. (PD/PI), Khan, S. A. (Co-Investigator) & Kocherginsky, M. (Co-Investigator)

  National Institute of Environmental Health Sciences

  1/23/24 → 10/31/28

  Project: Research project

• Prot #KT-US-472-0141: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleuce

  Karmali, R. (PD/PI)

  ICON Clinical Research Limited, Kite Pharma, Inc.

  1/22/24 → 1/22/27

  Project: Research project

• CEGIR - OATFEED

  Gonsalves, N. P. (PD/PI), Gonsalves, N. P. (PD/PI), Hirano, I. (Co-Investigator) & Hirano, I. (Co-Investigator)

  Cincinnati Children's Hospital Medical Center

  1/22/24 → 8/31/25

  Project: Research project

• Donor nonclassical monocytes mediate primary graft dysfunction and remote organ injury following lung transplant surgery

  Bharat, A. (PD/PI), Budinger, G. S. (PD/PI), Lecuona, E. (Co-Investigator), Wu, Q. (Co-Investigator) & Yan, Y. (Co-Investigator)

  National Heart, Lung, and Blood Institute

  1/20/24 → 12/31/28

  Project: Research project

• Prot #EP0031-101: A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies

  Patel, J. D. (PD/PI)

  Theradex, Ellipses Pharma Limited

  1/19/24 → 1/19/27

  Project: Research project

• Prot #EFC17801: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study, Followed by Open-Label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants with Chronic Lung Allograft Dysfunction

  Arunachalam, A. (PD/PI)

  ICON Clinical Research, LLC, Sanofi US Services Inc.

  1/19/24 → 1/19/27

  Project: Research project

• Prot #1403-0019: Brightline-4: A Phase III Open-Label, Single-Arm, Multi-Center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients with Treatment-Naïve or Pre-Treated Advanced Dedifferentiated Liposarcoma

  Hermida de Viveiros, P. A. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  1/18/24 → 1/18/27

  Project: Research project

• Prot #CV006: TANDEM II: Early Feasibility Study of the Duo Transcatheter Tricuspid Coaptation Valve System in Patients with Tricuspid Regurgitation

  Davidson, C. J. (PD/PI)

  North American Science Associates, LLC, CroiValve Limited

  1/17/24 → 1/17/27

  Project: Research project

• Prot #218224: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, ParallelGroup Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

  Bemiss, B. (PD/PI)

  PPD Investigator Services, LLC, GlaxoSmithKline LLC

  1/17/24 → 1/17/27

  Project: Research project

• Prot #1425-0003: A Phase IIa, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients with Crohn`s Disease (CD) Receiving Ustekinu

  Hanauer, S. B. (PD/PI)

  Quintiles, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.

  1/17/24 → 1/17/27

  Project: Research project

• : Prot #RNLC3132: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)

  Cheung, A.C.-W. (PD/PI)

  Quintiles, Inc., Salix Pharmaceuticals, Inc.

  1/12/24 → 1/12/27

  Project: Research project

• Histology and Microenvironment Characterization of Canine Tumors

  Pollack, S. M. (PD/PI) & Pollack, S. M. (PD/PI)

  Obsidian Therapeutics

  1/5/24 → 1/4/26

  Project: Research project

• Original CTA

  Gradishar, W. J. (PD/PI)

  Worldwide Clinical Trials, Inc., Stemline Therapeutics, Inc.

  1/4/24 → 1/4/27

  Project: Research project

• Prot #23-001: PEERLESS II Study, FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism

  Schimmel, D. R. (PD/PI)

  Inari Medical, Inc

  1/2/24 → 1/2/27

  Project: Research project